Aspirin for preventing the recurrence of venous thromboembolism.

By C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, M. Silingardi, M. Bianchi, M. Moia, W. Ageno, M. Vandelli and 2 more. New England Journal of Medicine, 2012

615 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/f1e4a234c7a8db02850aec4cd68a9fb60e7108f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jeroen J. Bax
2. Jose Luis Zamorano
3. M. Levi
4. P. Lancellotti
5. G. Agnelli

In Hematology

1. H. Versteeg
2. Pieter H. Reitsma
3. J. Heemskerk
4. M. Levi
5. S. Konstantinides

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides
3. H. Büller

Citations in the corpus

• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “In two recent trials with a total of 1224 patients, extended therapy with aspirin (after termination of standard oral anticoagulation) was associated with a 30–35% reduction in the risk of recurrence after unprovoked DVT and/or PE.(368,369) This corresponds to less than half of the risk reduction ac”
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, result): “associated with a 30 35% reduction in the risk of recurrence compared with placebo (Supplementary Data Table 15).(355,356) However, more recently, another trial demonstrated the superiority of anticoagulation with rivaroxaban, either 20 or 10 mg o.”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “associated with a 30–35% reduction in the risk of recurrence after unprovoked DVT and/or PE.(368,369) This corresponds to less than half of the risk reduction achieved by oral anticoagulants; on the other hand,”
• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017, neutral): “New England Journal of Medicine, 376(13), 1211-1222.”
• New fundamentals in hemostasis. (2013, background): “Second, a recent clinical trial showed that treatment with aspirin strongly reduced the risk of recurrent VTE without increasing thrombotic risk (21).”
• Thrombosis: tangled up in NETs. (2014, background): “Platelets and platelet adhesion to VWF are essential to thrombus generation,(34,58) and 2 recent clinical trials showed that aspirin, long regarded as an antiplatelet therapy, prevents venous thromboembolism recurrence.(92,93) Interestingly, aspirin can also inhibit NETosis invitro.”